Benzimidazolyl derivatives

Benzimidazolyl derivatives of formula I

• wherein
• Ar1 is selected from aromatic hydrocarbons containing 6 to 14 carbon atoms and ethylenical unsaturated or aromatic heterocyclic residues containing 3 to 10 carbon atoms and one or two heteroatoms, independently selected from N, O and S,
• E is (CR5R6)n, wherein n is 1 or 2,
• D is (CR5R6)k, wherein k is 0 or 1,
• R5, R6 are in each case independently from one another selected from H and A;
• −8, R9 and R10 are independently selected from a group consisting of H, A, cycloalkyl comprising 3 to 7 carbon atoms, Hal, CH2Hal, CH(Hal)2, C(Hal)3, NO2, (CH2)nCN, OHet, N(R11)Het, NR11COR13, NR11COOR13 CONR11R12COOR13, (CR5R6)kHet, O(CR5R6)kHet, N(R11)(CR5R6)kHet, (CR5R6)kNR11R12, (CR5R6)kOR13, O(CR5R6)kNR11R12, NR11(CR5R6)kNR11R12, O(CR5R6)kR13, NR11(CR5R6)kR13, O(CR5R6)kOR13, NR11(CR5R6)kOR13, (CH2)nNR11R12, (CH2)nO(CH2)kNR11R12, (CH2)nNR11(CH2)kNR11R12, (CH2)nO(CH2)kOR11, (CH2)nNR11(CH2)kOR12, (CH2)nCOOR13, (CH2)nCOR13, (CH2)nCONR11R12, (CH2)nNR11COR13, (CH2)nNR11CONR11R12, (CH2)nNR11SO2A, (CH2)nSO2NR11R12, (CH2)nS(O)uR13 (CH2)nOC(O)R13, (CH2)nCOR13, (CH2)nSR11, CH═N—OA, CH2CH═N—OA, (CH2)nNHOA, (CH2)nCH═N—R11, (CH2)nOC(O)NR11R12, (CH2)nNR11COOR13, (CH2)nN(R11)CH2CH2OR13, (CH2)nN(R11)CH2CH2OCF3, (CH2)nN(R11)C(R13)HCOOR12, (CH2)nN(R11)C(R13)HCOR11, (CH2)nN(R11)CH2CH2N(R12)CH2COOR11, (CH2)nN(R11)CH2CH2NR11R12, CH═CHCOOR13, CH═CHCH2NR11R12, CH═CHCH2NR11R12, CH═CHCH2OR13, (CH2)nN(COOR13)COOR14, (CH2)nN(CONH2)COOR13, (CH2)nN(CONH2)CONH2, (CH2)nN(CH2COOR13)COOR14, (CH2)nN(CH2CONH2)COOR13 (CH2)nN(CH2CONH2)CONH2, (CH2)nCHR13COR14, (CH2)nCHR13COOR14, (CH2)nCHR13CH2OR14, (CH2)nOCN and (CH2)nNCO, wherein
• R11, R12 are independently selected from a group consisting of H, A, (CH2)mAr3 and (CH2)mHet, or in NR11R12,
• R11 and R12 form, together with the N-atom they are bound to, a 5-, 6- or 7-membered heterocyclus which optionally contains 1 or 2 additional hetero atoms, selected from N, O and S,
• R13, R14 are independently selected from a group consisting of H, Hal, A, (CH2)mAr4 and (CH2)mHet,
• A is selected from the group consisting of alkyl, alkenyl, cycloalkyl, alkylenecycloalkyl, alkoxy, alkoxyalkyl and saturated heterocyclyl, preferably from the group consisting of alkyl, alkenyl, cycloalkyl, alkylenecycloalkyl, alkoxy and alkoxyalkyl,
• Ar3, Ar4 are independently from one another aromatic hydrocarbon residues comprising 5 to 12 and preferably 5 to 10 carbon atoms which are optionally substituted by one or more substitutents, selected from a group consisting of A, Hal, NO2, CN, OR15, NR15R16, COOR15, CONR15R16, NR15COR16, NR15CONR15R16, NR16SO2A, COR15, SO2NR15R16, S(O)uA and OOCR15,
• Het is a saturated, unsaturated or aromatic heterocyclic residue which is optionally substituted by one or more substitutents, selected from a group consisting of A, Hal, NO2, CN, OR15, NR15R16, COOR15, CONR15R16, NR15COR16, NR15CONR15R16, NR16SO2A, COR15, SO2NR15R16, S(O)uA and OOCR15,
• R15, R16 are independently selected from a group consisting of H, A, and (CH2)mAr6, wherein
• Ar6 is a 5- or 6-membered aromatic hydrocarbon which is optionally substituted by one or more substitutents selected from a group consisting of methyl, ethyl, propyl, 2-propyl, tert.-butyl, Hal, CN, OH, NH2 and CF3,
• k, n and m are independently of one another 0, 1, 2, 3, 4, or 5,
• Y is selected from O, S, NR21, C(R22)—NO2, C(R22)—CN and C(CN)2, wherein
• R21 is independently selected from the meanings given for R13, R14 and
• R22 is independently selected from the meanings given for R11, R12,
• p is independently in each case 0, 1, 2, 3, 4 or 5,
• q is 0, 1, 2, 3 or 4, preferably 0, 1 or 2,
• u is 0, 1, 2 or 3, preferably 0, 1 or 2,
• and
• Hal is independently selected from a group consisting of F, Cl, Br and I;
• the tautomeric forms thereof;
• and the pharmaceutically acceptable derivatives, salts and solvates thereof.